Biocept plans public sale of 6,302,521 shares to fund sales, marketing

Offer sells common stock through bookrunners Aegis Capital and Feltl

By Devika Patel

Knoxville, Tenn., Jan. 21 – Biocept, Inc. will sell 6,302,521 common shares in a public offering with a 45-day greenshoe option of 945,378 additional shares, according to a Form S-1/A filed Wednesday with the Securities and Exchange Commission. The company has registered up to $17.25 million of stock for the sale.

Aegis Capital Corp. and Feltl and Co. are the bookrunning managers.

Proceeds will be used to hire sales and marketing personnel and support increased sales and marketing activities; for research and development, clinical utility studies and enhancements of tests and services; to acquire equipment, implement automation and scale the company's capabilities to prepare for significant test volume; and for general corporate purposes, operations and business expansion.

The cancer diagnostics company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.